

Drug Monograph

Drug Name: **Sertraline 150 mg and 200 mg capsules**
 Drug Class: **Central Nervous System: Selective Serotonin Reuptake Inhibitors (SSRIs)**
 Prepared For: MO HealthNet
 Prepared By: Conduent

☒ **New Criteria**

☐ **Revision of Existing Criteria**

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: Sertraline is now available in a 150 mg and a 200 mg capsule.

Manufacturer: Distributed by: Almatica Pharma LLC, Morristown, NJ 07960.

Indications: Sertraline HCl is a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of: 1) major depressive disorder (MDD) in adults; and 2) obsessive-compulsive disorder (OCD) in adults and pediatric patients ≥ 6 years.

Costs: \$147 per 30 capsules Wholesale Acquisition Cost

Summary of Findings: The MO Healthnet Division recommends adding this drug to the current SSRI clinical edit and to the current psychotropic polypharmacy clinical edit.

Status Recommendation:

<input checked="" type="checkbox"/> Clinical Edit	<input type="checkbox"/> PA Required
<input type="checkbox"/> Open Access	<input type="checkbox"/> PDL

Type of PA Criteria:

<input checked="" type="checkbox"/> Appropriate Indications	<input type="checkbox"/> Non-Preferred
<input type="checkbox"/> No PA Required	<input type="checkbox"/> Preferred

Prepared by: April Ash, PharmD
 Date: January 7, 2022